Winona Tse, MD

Our research team includes: Mindy Lopez, CCRC, ACRP-PM, Clinical Research Manager Joan Bratton, BA, Clinical Research Associate Christina Rosario, BA, Clinical Research Coordinator II • A Phase 3, Twelve-week, Multi-Center, Multinational, Randomized, Double-Blind, Double-Dummy, Parallel Group Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily Compared to its Individual Components in Subjects With Early Parkinson’s Disease and to a Calibration Arm of Pramipexole ER. • An Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations ("OFF" Episodes) • A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Trial to Evaluate the Efficacy and Safety of a Single Treatment of DaxibotulinumtoxinA for Injection in Adults with Isolated Cervical Dystonia (ASPEN-1) • A Phase 3, Open-Label, Multi-Center Trial to Evaluate the Long-Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in Adults with Isolated Cervical Dystonia (ASPEN-OLS) • RESTORE: A clinical study of patients with symptomatic neuRogenic orthostatic hypotEnsion to assess Sustained effecTs Of dRoxidopa thErapy • A Randomized, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of SEP-363856 in Subjects with Parkinson’s Disease Psychosis • A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants with Progressive Supranuclear Palsy • PL101-LID201 - A 14 week, double-blind, randomized three arm, parallel group study to assess the efficacy and safety of two doses of pridopidine versus placebo for the treatment of levodopa induced dyskinesias in Patients with Parkinson’s disease.